Journal
ONCOGENE
Volume 26, Issue 50, Pages 7163-7169Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1210528
Keywords
herceptin; trastuzumab; ERBB2; breast cancer; phosphorylation; tyrosine kinase
Ask authors/readers for more resources
Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available